Table 1 Demographic Data of the Study and Control Groups
From: High-dose antioxidants for central serous chorioretinopathy; The randomized placebo-controlled study
Study group (group A) | Control group (group B) | p-value | |
|---|---|---|---|
Age (years ± SD) | 41.28 ± 5.07 | 39.48 ± 6.95 | 0.27 |
Sex (M/F) | 23/6 | 25/4 | 0.49 |
Duration before diagnosis (days ± SD) | 13.24 ± 9.65 | 17.55 ± 9.66 | 0.09 |
Initial VA (logMAR ± SD) | 0.23 ± 0.27 | 0.27 ± 0.20 | 0.59 |
Initial CMT (microns ± SD) | 524.28 ± 175.95 | 508.69 ± 135.31 | 0.70 |
FA findings at baseline | |||
- inkblot leakage | 26 | 26 | - |
- smokestack leakage | 3 | 3 | 1.00 |